VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of medicines for the treatment of cancer, and respiratory and autoimmune diseases. The company focuses on the development of small molecule product candidates targeting toll-like receptor 8 (TLR8) agonists and antagonists. Its product pipeline comprises VTX-2337, a small molecule TLR8 agonist that stimulates myeloid dendritic cells and monocytes, and enhances natural killer cell responses for the treatment of solid tumors, ovarian and breast cancers, and NHL and SCHN; VTX-1463, a stand alone agent for the treatment of seasonal and perennial allergies; TLR8 antagonists for the treatment of autoimmune diseases; and multiple compounds that are treated as vaccine adjuvants. The company has a strategic agreement/collaboration with Celgene Corporation. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Seattle, Washington with operations in San Diego.from http://www.ventirx.com/about/index.html
Patents 141show all
- 53A61K - Preparations for medical, dental, or toilet purposes
- 40C07D - Heterocyclic compounds
- 15B82Y - Specific uses or applications of nanostructures
- 14C07K - Peptides
Clinical Trials 1show all
SEC Filings show all
Crunchbase Investment Rounds
|Date||Amount||Round||Valuation||Lead Investor||Other Investors|
|2014-09-23||$50,602,514||Series B||ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, MedImmune Ventures, Celgene|
|2010-01-13||$25,000,000||Series A||MedImmune Ventures||ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates|
|2007-03-06||$26,600,000||Series A||Frazier Healthcare Partners||Domain Associates, ARCH Venture Partners|
SEC Form D Funding Events
- Robert M. Hershberg, M.D., Ph.D.
Executive Officer, Director
- Patrick Heron
- Nicole Vitullo
- Steven Gillis, Ph.D.
- Elliot Grossbard, M.D.
- Atul Saran
- Kent Snyder
- Ron Laufer
- Kathleen Fanning